The India cancer medicine price revision 2026 lowers the maximum retail price of 543 anti-cancer medicine brands and pack sizes, with the new rates taking effect on 9 November 2026. The National Pharmaceutical Pricing Authority, or NPPA, published the revised list on 28 October 2026, according to press reports, following the government’s 17 October decision to rationalise trade margins on 137 non-scheduled anti-cancer medicines. Some listed prices have fallen sharply, while others, including some innovator brands, are reported to be unchanged. This article explains what was published, what the examples show and what we could not verify.
Key takeaways from the India cancer medicine price revision 2026
- The NPPA list covers 543 brands and pack sizes of anti-cancer medicines, with revised maximum retail prices effective 9 November 2026.
- The list follows a decision on 17 October to cap trade margins at 30% on 137 non-scheduled anti-cancer medicines.
- Reported cuts reach 93% in the sharpest case, and exceed 90% in some cases, but they vary and some prices are reported unchanged.
- The list reflects company submissions up to 27 October and will be updated as manufacturers submit revised prices.
- We could not check individual prices against the official NPPA schedule, so the examples below come from press reports.
What the NPPA published in the India cancer medicine price revision 2026
According to reports, the revised list includes medicines used for breast, prostate, colon, ovarian and cervical cancers, along with immunotherapy, targeted therapy and supportive-care products given to chemotherapy patients. It applies to brands that fall under the trade-margin cap, not to every cancer medicine on the market. Retailers and hospitals are expected to charge the revised prices from 9 November, and manufacturers are expected to pass the changes through the supply chain, with state drug controllers monitoring compliance. The official body is described at the NPPA website.
How the 30% trade margin cap works
The cap limits the trade margin to 30% of the maximum retail price, excluding GST, under the Drugs (Prices Control) Order, 2013. Reports note that a 30% margin on MRP is equal to a markup of about 42.86% on the price paid by the stockist or distributor. By our own arithmetic that is 30 divided by 70. The policy applies to non-scheduled medicines, meaning drugs not covered by notified ceiling prices. Scheduled medicines are priced separately through ceiling prices. Our earlier reports on the cap are available in Cancer Medicine Price Reduction in India and India Caps Cancer Drug Trade Margins at 30% of MRP.
Examples in the India cancer medicine price revision 2026
Press reports give several examples. Anarzole, an anastrozole 1 mg tablet from RPG Life Sciences in a pack of 10, goes from Rs 695.76 to Rs 73. Azacytin, an azacitidine injection from Dr Reddy’s, goes from Rs 6,337 to Rs 1,495.04. Bevacizab, a 4 ml bevacizumab vial from Abbott Healthcare, goes from Rs 21,767.70 to Rs 5,930.13. Dasanat 20, a dasatinib tablet, goes from Rs 2,812.50 to Rs 1,085.93. By our own calculation, those are cuts of roughly 89.5%, 76.4%, 72.8% and 61.4%. These figures come from press accounts and have not been checked against the NPPA schedule, so patients should rely on the label and the official list.
What did not change in the India cancer medicine price revision 2026
One press report says the MRPs of some originator products, such as Roche’s Avastin (bevacizumab) and Keytruda (pembrolizumab), and all versions of nivolumab, were unchanged, while biosimilars of bevacizumab fell by 69% to 86%. It quotes an oncologist suggesting unchanged originator prices may mean their margins were already reasonable. We could not verify those entries independently. The same report quotes a drug-access group saying the exclusion of free volumes under patient assistance programmes blunted cuts on patented drugs and that companies self-report MRPs without verification. Those are the critics’ views.
What patients can do after the India cancer medicine price revision 2026
Patients and carers can check the printed price on the pack from 9 November and compare it with the NPPA list for their brand. If a pharmacy charges above the listed MRP, complaints can be taken to the state drug controller or the NPPA. Doctors may also be able to suggest a different brand of the same medicine, but any change of medicine should be a clinical decision. This article is general information and not medical advice.
Market context from Acumen Research and Consulting
Acumen Research and Consulting’s Cancer Therapeutics Market report values the global market at USD 193.7 billion in 2024 and projects USD 381.5 billion by 2033, a CAGR of 7.9% for 2025 to 2033. It says North America had the largest value, about USD 71.7 billion in 2024, and Asia Pacific is the fastest-growing region at more than 8.8%. The page carries a last-updated date of 2019 that conflicts with its 2024 base year, so the numbers are estimates. They are global and do not measure the Indian price changes.
Timeline of the India cancer medicine price revision 2026
- 2019: an earlier margin cap covers 42 anti-cancer drugs.
- 17 October 2026: the government decides to cap trade margins on 137 non-scheduled anti-cancer medicines.
- 27 October 2026: cut-off for company price submissions used in the list.
- 28 October 2026: revised list for 543 brands is reported.
- 9 November 2026: new MRPs take effect.
General background: why trade margins matter
Between a manufacturer and a patient, medicines pass through distributors and retailers who each add a margin. Where the printed MRP is set well above what the trade pays, patients can end up paying a large markup, which is the problem the margin cap tackles. Hospitals that buy directly may add their own charges.
Our analysis of the India cancer medicine price revision 2026
In our assessment, the India cancer medicine price revision 2026 is meaningful for many generic and biosimilar brands, where MRPs appear to have been set far above trade prices, and less so for products whose prices are unchanged. The government has estimated broader savings of around Rs 2,500 crore a year, according to reports, but that is an official estimate and we cannot confirm it. The real test is whether patients see the new prices at the counter from 9 November.
What is not disclosed in the India cancer medicine price revision 2026
- The official NPPA notice number and the full price-by-price schedule as we could read it.
- How many of the 543 entries are unchanged.
- How compliance will be checked.
- What happens to stock already printed with old prices.
Risks and caveats
The list will be updated as companies submit prices; the Department of Pharmaceuticals publishes related policy material at pharmaceuticals.gov.in. Press-reported examples may contain errors. This article is news reporting and not medical or legal advice.
What to watch next after the India cancer medicine price revision 2026
- Updates to the NPPA list.
- Retail compliance from 9 November.
- Any legal challenge or industry response.
FAQ
When do the new prices apply?
From 9 November 2026, according to reports.
How many brands are covered?
543 brands and pack sizes of anti-cancer medicines.
Are all cancer medicine prices lower?
No. Reductions vary and some prices are reported unchanged.
How we reported this: we relied on press reports of the NPPA list, the NPPA website and the Acumen Research and Consulting report cited above. Our calculations are labelled. Last updated 29 October 2026. This is news reporting and not advice.